Global Glaucoma Surgery Market Segmentation, By Target (Trabecular Meshwork, Suprachoroidal Space, and Others), Surgery Type (Conventional Glaucoma Surgeries and Minimally Invasive Glaucoma Surgeries), Product (Glaucoma Drainage Devices, Glaucoma Laser Devices, and Implants and Stents), End-User (Eye Hospitals, Ophthalmology Clinics, and Outpatient Surgical Centers) – Industry Trends and Forecast to 2032
Glaucoma Surgery Market Analysis
The glaucoma surgery market has experienced significant advancements in recent years, particularly with the introduction of minimally invasive surgical techniques (MIGS). MIGS procedures, such as the iStent and Xen Gel Stent, offer safer and more effective alternatives to traditional surgeries such as trabeculectomy. These techniques involve smaller incisions, reduced recovery times, and lower complication risks, contributing to faster adoption among patients and surgeons.
Technology advancements in surgical devices, such as femtosecond lasers, have also improved precision in glaucoma surgery. Femtosecond lasers allow for more controlled tissue removal, improving outcomes and reducing post-operative complications. In addition, the integration of digital platforms in monitoring intraocular pressure and disease progression has enhanced personalized treatment strategies.
The use of surgical robots, though still emerging, holds great promise in further improving accuracy and minimizing human error. As these technologies continue to evolve, the market is expected to grow rapidly, driven by a rising aging population and increased awareness of glaucoma's potential to cause blindness if untreated. The combination of innovative surgical techniques and technology advancements is transforming the glaucoma surgery market, enhancing both treatment efficacy and patient outcomes.
Glaucoma Surgery Market Size
The global glaucoma surgery market size was valued at USD 3.01 billion in 2024 and is projected to reach USD 5.97 billion by 2032, with a CAGR of 8.94% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Glaucoma Surgery Market Trends
“Minimally Invasive Glaucoma Surgery (MIGS) Advancements”
One specific trend helping the growth of the glaucoma surgery market is the increasing adoption of Minimally Invasive Glaucoma Surgery (MIGS). MIGS offers significant advantages, including faster recovery times, reduced risk of complications, and less discomfort for patients compared to traditional glaucoma surgeries. This trend is driven by the growing demand for safer, more efficient treatment options. For instance, devices such as the iStent inject, which is used to reduce intraocular pressure in glaucoma patients, have seen widespread adoption. These procedures are being increasingly recommended as a preferred option by healthcare providers, contributing to the market's expansion as patient demand for less invasive solutions grows.
Report Scope and Glaucoma Surgery Market Segmentation
|
Attributes
|
Glaucoma Surgery Key Market Insights
|
|
Segments Covered
|
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Key Market Players
|
Novartis AG (Switzerland), Glaukos Corporation (U.S.), Abbott (U.S.), New World Medical, Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Bausch & Lomb Incorporated (U.S.), TOPCON CORPORATION (Japan), Lumenis (U.S.), Allergan (Ireland), Teva Pharmaceutical Industries Ltd (Israel), NIDEK CO., LTD (Japan), HAAG-STREIT GROUP (Switzerland), Essilor (France), Ziemer Ophthalmic Systems (Switzerland), Carl Zeiss Meditec (Germany), Sonomed Escalon (U.S.), HumanOptics (Germany), and PhysIOL (Belgium)
|
|
Market Opportunities
|
|
|
Value Added Data Infosets
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Glaucoma Surgery Market Definition
Glaucoma surgery refers to a set of procedures aimed at lowering intraocular pressure (IOP) to prevent further damage to the optic nerve in individuals with glaucoma. Common types include trabeculectomy, where a small drainage hole is created in the eye to allow fluid to drain, and tube shunt surgery, which involves implanting a tube to help with fluid drainage. Laser surgeries, such as selective laser trabeculoplasty (SLT) and laser peripheral iridotomy, may also be performed to improve fluid drainage or reduce eye pressure. These procedures help manage glaucoma when medications or other treatments are insufficient.
Glaucoma Surgery Market Dynamics
Drivers
- Rising Prevalence of Glaucoma
The rising prevalence of glaucoma, particularly in high-risk groups such as the elderly, is significantly driving the demand for glaucoma surgeries. Glaucoma is the second-leading cause of blindness globally, with the World Health Organization estimating that over 76 million people will be affected by 2020, a number projected to increase with an aging population. Early detection programs are increasingly common, enabling higher diagnosis rates, which consequently lead to a rise in surgical interventions. For instance, the U.S. Centers for Disease Control and Prevention (CDC) reports that early screening has led to earlier treatment, reducing the risk of vision loss and increasing the demand for surgeries, particularly minimally invasive procedures.
- Shift Towards Personalized Treatment Plans
The shift towards personalized treatment plans is significantly driving the glaucoma surgery market. Tailored approaches, considering a patient's unique genetic makeup, health history, and response to medication, have improved surgical outcomes. For instance, personalized glaucoma treatments, such as customized laser therapy or specific MIGS procedures, enhance effectiveness and minimize risks. This approach ensures that each patient receives the most appropriate surgical solution, leading to higher success rates and faster recovery times. As a result, more patients are opting for surgery, knowing their treatment will be individualized for optimal results. This trend boosts demand for advanced surgical techniques and drives growth in the glaucoma surgery market.
Opportunities
- Advancements in Surgical Techniques
The introduction of Minimally Invasive Glaucoma Surgery (MIGS) has significantly advanced glaucoma treatment, creating new opportunities in the market. MIGS techniques, such as the iStent and Xen Gel Stent, require smaller incisions, which reduce patient trauma and recovery times compared to traditional surgeries. MIGS has proven to be effective in lowering intraocular pressure with fewer complications, making it an attractive option for both patients and surgeons. This technique is especially beneficial for patients with mild to moderate glaucoma. The growing adoption of MIGS is expanding the market, with procedures expected to increase as more healthcare providers incorporate these advanced technologies into their practices.
- Government Support for Eye Care
Governments worldwide are increasingly investing in eye care infrastructure, especially in emerging markets, creating significant opportunities for the glaucoma surgery market. For instance, India's National Programme for Control of Blindness and Visual Impairment (NPCB) allocates funds for eye care facilities, improving glaucoma diagnosis and treatment. Similarly, the African Vision 2020 initiative has led to better access to eye care services, driving demand for glaucoma surgeries in Africa. These government-driven initiatives promote early glaucoma detection and surgical interventions, improving patient outcomes. As a result, eye care programs, along with expanding healthcare access, stimulate market growth by encouraging more patients to seek glaucoma treatment and surgery.
Restraints/Challenges
- High Cost of Surgery
The high cost of surgery is a significant restraint in the glaucoma surgery market. Advanced procedures such as trabeculectomies or the use of glaucoma drainage devices are expensive, making them inaccessible for patients in lower-income regions. Healthcare systems in developing countries, which face budget constraints, often cannot afford these costly treatments, limiting their adoption. In addition, the high cost increases the financial burden on patients, deterring them from seeking treatment or opting for alternative, less effective options. As a result, the market faces challenges in reaching a broader patient base, impeding growth and limiting the widespread implementation of advanced glaucoma surgical solutions.
- Long Recovery Time
The long recovery time associated with glaucoma surgeries is a significant challenge for the market. Post-surgical recovery can be prolonged, requiring extensive follow-up care and monitoring to ensure successful outcomes. This can strain healthcare resources, particularly in regions with limited medical infrastructure. Patients often face discomfort, reduced quality of life, and the inconvenience of frequent visits to healthcare facilities. The recovery period can also lead to dissatisfaction due to prolonged healing times and potential complications. As a result, patients may hesitate to undergo surgery, opting for less invasive or non-surgical treatments. This trend hampers the overall growth of the glaucoma surgery market.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Glaucoma Surgery Market Scope
The market is segmented on the basis of target, surgery type, product and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Target
- Trabecular Meshwork
- Suprachoroidal Space
- Others
Surgery Type
- Conventional Glaucoma Surgeries
- Minimally Invasive Glaucoma Surgeries
Product
- Glaucoma Drainage Devices
- Glaucoma Laser Devices
- Implants and Stents
End-User
- Eye Hospitals
- Ophthalmology Clinics
- Outpatient Surgical Centers
Glaucoma Surgery Market Regional Analysis
The market is analysed and market size insights and trends are provided by country, target, surgery type, product and end-user as referenced above.
The countries covered in the market report are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, U.A.E, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA)
North America is expected to dominate the glaucoma surgery market due to the presence of leading market players, efficient reimbursement policies, and public health programs such as Eye America and Vision US. In addition, increasing awareness about glaucoma and the early availability of advanced products contribute to the region's market leadership.
Europe is expected to show significant growth in the glaucoma surgery market due to the increasing shift towards minimally invasive procedures for glaucoma treatment. The region's rapid technological advancements in glaucoma surgery devices further drive market expansion. These factors, coupled with rising healthcare demand, position Europe as a key growth area in this market.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Glaucoma Surgery Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Glaucoma Surgery Market Leaders Operating in the Market Are:
- Novartis AG (Switzerland)
- Glaukos Corporation (U.S.)
- Abbott (U.S.)
- New World Medical, Inc. (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- Bausch & Lomb Incorporated (U.S.)
- TOPCON CORPORATION (Japan)
- Lumenis (U.S.)
- Allergan (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- NIDEK CO., LTD (Japan)
- HAAG-STREIT GROUP (Switzerland)
- Essilor (France)
- Ziemer Ophthalmic Systems (Switzerland)
- Carl Zeiss Meditec (Germany)
- Sonomed Escalon (U.S.)
- HumanOptics (Germany)
- PhysIOL (Belgium)
Latest Developments in Glaucoma Surgery Market
- In November 2023, Glaukos Corporation announced that the FDA approved its iStent inject Trabecular Micro-Bypass System for treating open-angle glaucoma (OAG). This minimally invasive glaucoma surgery (MIGS) device is implanted in the eye's trabecular meshwork to enhance drainage and lower intraocular pressure (IOP), providing a more effective and safer treatment option for glaucoma patients
- In October 2023, Johnson & Johnson Vision received CE Mark approval for its Xact Robotic System for glaucoma surgery. This robotic-assisted surgical platform is designed to enhance surgeon precision and control during MIGS procedures. The system aims to improve the accuracy of surgeries, offering better outcomes and fewer complications in treating glaucoma
- In September 2023, Alcon launched its new Hydrus Microstent in the U.S. market. This MIGS device helps lower intraocular pressure (IOP) by creating a bypass channel for aqueous humor drainage in the eye. The Hydrus Microstent offers a promising solution for patients suffering from glaucoma, improving drainage and minimizing surgical risks
- In August 2023, Bausch + Lomb announced that its enVista Aspire intermediate-optimized monofocal and toric intraocular lenses (IOLs) received FDA approval. These lenses are designed for use in cataract and glaucoma surgeries, providing patients with clear, continuous vision at all distances after surgery. The enVista Aspire IOLs improve visual quality and patient satisfaction
- In July 2023, Nova Eye Medical, Inc. received FDA clearance for its iClear Microstent. This MIGS device aims to reduce intraocular pressure (IOP) by creating a new drainage pathway for aqueous humor in the eye. The iClear Microstent offers a less invasive solution for glaucoma patients, reducing the risk of complications and improving treatment outcomes
SKU-